Literature DB >> 16418703

Assessment of chronic exposure to MDMA in a group of consumers by segmental hair analysis.

Simona Pichini1, Sandra Poudevida, Mitona Pujadas, Ester Menoyo, Roberta Pacifici, Magí Farré, Rafael de la Torre.   

Abstract

The suitability of segmental hair analysis of MDMA to monitor past chronic exposure to the drug was investigated in a follow-up study of ecstasy consumers. The purpose, among others, was to look for an objective biomarker of the history of drug consumption. Thirteen naturally colored hair samples were used to assess possible association between hair concentration of MDMA in 1-, 5-, and 9-cm segments and self-reported use in the last 1, 6, and 12 months. Agreement between the self-reported data given by the subjects on their "ecstasy" use in the previous month and MDMA hair concentration was good (r = 0.92) in all the examined subjects, with the exception of 2 individuals who declared a high consumption of the drug (12 tablets in the last month). When comparing the subjects' declaration of tablets consumed per month within the last 6 months, concordance with the hair MDMA values decreased and no correlation seemed to exist between the mean number of tablets consumed in the last 12 months and the concentration of MDMA in hair. However, when grouping subjects with a similar level of declared drug use (independently of whether in the previous month, last 6 months and last 12 months) and comparing the data with the mean MDMA concentrations found in the corresponding hair segments, an excellent level of agreement was found in groups of subjects consuming <5 tablets of MDMA per month (r = 0.93). Although the present findings were obtained from a small group of individuals and are intended as preliminary results, we can conclude that a cutoff of 0.5 ng MDMA per mg hair seems reasonable to assess drug consumption, unless the level of consumption was once per month in the last 12 months. Doubling the monthly consumption increases hair MDMA by around 1 ng/mg hair up to a level of 4 consumed tablets a month. It does not seem possible to draw definitive conclusions from higher concentrations in hair samples.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16418703     DOI: 10.1097/01.ftd.0000189900.01060.92

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

1.  COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users.

Authors:  Antonio Verdejo-García; Ana Beatriz Fagundo; Aida Cuenca; Joan Rodriguez; Elisabet Cuyás; Klaus Langohr; Susana de Sola Llopis; Ester Civit; Magí Farré; Jordi Peña-Casanova; Rafael de la Torre
Journal:  Neuropsychopharmacology       Date:  2013-02-28       Impact factor: 7.853

2.  Auditory event-related potentials (P3) and cognitive performance in recreational ecstasy polydrug users: evidence from a 12-month longitudinal study.

Authors:  Susana de Sola; Thais Tarancón; Jordi Peña-Casanova; Josep María Espadaler; Klaus Langohr; Sandra Poudevida; Magí Farré; Antonio Verdejo-García; Rafael de la Torre
Journal:  Psychopharmacology (Berl)       Date:  2008-06-26       Impact factor: 4.530

3.  The influence of genetic and environmental factors among MDMA users in cognitive performance.

Authors:  Elisabet Cuyàs; Antonio Verdejo-García; Ana Beatriz Fagundo; Olha Khymenets; Joan Rodríguez; Aida Cuenca; Susana de Sola Llopis; Klaus Langohr; Jordi Peña-Casanova; Marta Torrens; Rocío Martín-Santos; Magí Farré; Rafael de la Torre
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

4.  Hair Testing for Classic Drugs of Abuse to Monitor Cocaine Use Disorder in Patients Following Transcranial Magnetic Stimulation Protocol Treatment.

Authors:  Maria Concetta Rotolo; Roberta Pacifici; Manuela Pellegrini; Stefano Cardullo; Luis J Gómez Pérez; Diego Cuppone; Luigi Gallimberti; Graziella Madeo
Journal:  Biology (Basel)       Date:  2021-05-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.